{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:38:56Z","timestamp":1757450336175},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,4,2]],"date-time":"2003-04-02T00:00:00Z","timestamp":1049241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J of Med Genetics Pt A"],"published-print":{"date-parts":[[2003,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The availability of molecular genetic tests for the identification of mutant gene carriers, and for assessing individual genetic response to pharmacologic agents, infectious agents, and other environmental exposures, is expected to result in the increased use of the molecular genetic testing laboratory by primary care physicians. However, a number of concerns have been raised about such testing including the need for safeguards to protect patient privacy, and if the interface between genetic testing laboratories and the ordering physician facilitates the appropriate clinical use of the test result. In this study, genetic counselors were surveyed to determine their practices with regard to the clinical issues of informed consent and confidentiality in the context of genetic testing, and to assess their level of satisfaction with the reporting practices of molecular genetic testing laboratories. The results of this survey revealed that there is variability in the practices of genetic counselors with regard to obtaining informed consent, and that there are areas for improvement with regard to molecular genetic test reports, particularly in terms of interpretation of results. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajmg.a.20196","type":"journal-article","created":{"date-parts":[[2003,5,30]],"date-time":"2003-05-30T10:04:53Z","timestamp":1054289093000},"page":"297-301","source":"Crossref","is-referenced-by-count":9,"title":["Interaction of genetic counselors with molecular genetic testing laboratories: Implications for non\u2010geneticist health care providers"],"prefix":"10.1002","volume":"119A","author":[{"given":"Margaret M.","family":"McGovern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Benach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Zinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,2]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"American College of Medical Genetics.2001.http:\/\/www.acmg.net."},{"key":"e_1_2_6_3_1","volume-title":"Assessing genetic risks: Implications for health and social policy","author":"Andrews L","year":"1994"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/324000"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.2.11.1119"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199703203361202"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001888-199308000-00013"},{"key":"e_1_2_6_8_1","volume-title":"Promoting safe and effective genetic testing in the United States: Final report of the task force on genetic testing","author":"Holtzman NA","year":"1997"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-200002000-00009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/301941"},{"key":"e_1_2_6_11_1","unstructured":"Preconception and Prenatal Carrier Screening for Cystic Fibrosis.2001.American College of Obstetrics and Gynecology and the American College of Medical Genetics."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00125817-200109000-00001"},{"key":"e_1_2_6_13_1","unstructured":"Secretary's Advisory Committee on Genetic Testing (SACGT).2000.Enhancing the oversight of genetic testing: Recommendations of the SACGThttp:\/\/ww4.od.nih.gov\/oba\/sacgt\/reports\/oversight_report.pdf."},{"key":"e_1_2_6_14_1","unstructured":"U.S. Congress.1992.Office of technology assessment cystic fibrosis and DNA Tests: Implications for carrier screening OTA\u2010BA\u2010532(Washington DC: U.S. Government Printing Office August 1992)."}],"container-title":["American Journal of Medical Genetics Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajmg.a.20196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajmg.a.20196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:02:47Z","timestamp":1696946567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajmg.a.20196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,2]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6,15]]}},"alternative-id":["10.1002\/ajmg.a.20196"],"URL":"https:\/\/doi.org\/10.1002\/ajmg.a.20196","archive":["Portico"],"relation":{},"ISSN":["1552-4825","1552-4833"],"issn-type":[{"value":"1552-4825","type":"print"},{"value":"1552-4833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,2]]}}}